STATEMENT OF STOCKHOLDERS' DEFICIT - 6 months ended Aug. 31, 2015 - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2015	$ 131,449	$ 114,993,920	$ (115,263,712)	$ (138,343)
Balance (in shares) at Feb. 28, 2015	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		109,683		109,683
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.		1,030,153		1,030,153
Net loss			(1,134,826)	(1,134,826)
Balance at Aug. 31, 2015	$ 131,449	$ 116,133,756	$ (116,398,538)	$ (133,333)
Balance (in shares) at Aug. 31, 2015	131,448,444